Cizzle Biotechnology Holdings PLC New Research Agreement with the University of York (1358X)
April 24 2023 - 2:00AM
UK Regulatory
TIDMCIZ
RNS Number : 1358X
Cizzle Biotechnology Holdings PLC
24 April 2023
24 April 2023
Cizzle Biotechnology Holdings Plc
("Cizzle Biotechnology" or the "Company")
New Research Agreement with the University of York for Cancer
Diagnosis and Therapy
Cizzle Biotechnology, the UK based diagnostics developer, is
pleased to announce that following successful results from its
current research programme with the University of York, due to end
this year, that it has today signed a new research agreement with
the University for the further development and validation of its
CIZ 1B biomarker technology for early stage cancer diagnosis and
other potential applications in cancer therapy.
This includes the evaluation of the Company's proprietary
biomarker for detecting a range of cancers in addition to the
existing programme for early lung cancer detection.
Highlights
-- New 12-month research and development agreement with the
University of York
-- Builds on successful outcomes of current research programme
on meeting key milestones for monoclonal antibody characterization
and assay platform optimization
-- All intellectual property rights arising from the work
to be owned by the Company
-- Extends access to state of the art facilities and world
leading scientists to support new solutions for early
cancer diagnostics and therapeutic tools
This new agreement will extend the work being conducted at the
university until 25th September 2024 and follows the successful
programme initially announced on 17 September 2021 and further
extended to June 2023. With a focus on the development and
validation of molecular tools with potential application in cancer
diagnosis or therapy, significant progress has been made in
characterising and optimizing the company's antibodies for use and
scale up into the configuration required for further clinical
trials ahead of the launch of commercial early stage lung cancer
assays. As in previous agreements, Cizzle Biotechnology will own
all intellectual property rights arising from the work which
strengthens the Company's position in creating new solutions for
early cancer diagnostics and therapeutic tools.
Cizzle Biotechnology was a spin out from the University of York
based on research and development by Professor Dawn Coverley at the
University and the first company from the university to be listed
on the London Stock Exchange. The company has a proven and
long-term commitment to work with the University of York which
provides access to its leading-edge research facilities and
expertise.
Commenting, Allan Syms, Executive Chairman of Cizzle
Biotechnology, said: "I am delighted to further extend our
relationship with the University of York and in particular the
leading-edge research being a carried out in Professor Dawn
Coverley's laboratories. The continuity and commitment of the
researchers at the University has been a key building block in the
development and commercialization of the CIZ1B biomarker for early
cancer diagnosis. The current research programme has met some
critical milestones, especially in optimising the platform and
antibodies required to scale up and bring to market our diagnostic
tests for early stage cancer detection. This new agreement will
continue our access to state of the art research facilities and
world leading scientists as we pursue our plans to bring early
detection tests for lung cancer and potentially other forms of
cancer."
Enquiries:
Cizzle Biotechnology Holdings Via IFC Advisory
plc
Allan Syms (Executive Chairman)
Allenby Capital Limited
John Depasquale
Alex Brearley +44(0) 20 33285656
Novum Securities Limited
Colin Rowbury
Jon Bellis +44(0) 20 7399 9400
IFC Advisory Limited
Tim Metcalfe
Florence Chandler +44(0) 20 3934 6630
About the Company
Cizzle Biotechnology is developing a blood test for the early
detection of lung cancer. Cizzle Biotechnology is a spin- out from
the University of York, founded in 2006 around the work of
Professor Coverley and colleagues. Its proof-of-concept prototype
test is based on the ability to detect a stable plasma biomarker, a
variant of CIZ1 known as CIZ1B. CIZ1 is a naturally occurring cell
nuclear protein involved in DNA replication, and the targeted CIZ1B
variant is highly correlated with early stage lung cancer.
For more information please see
https://cizzlebiotechnology.com
You can also follow the Company through its twitter account
@CizzlePlc and on LinkedIn.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCITMMTMTJTTMJ
(END) Dow Jones Newswires
April 24, 2023 02:00 ET (06:00 GMT)
Cizzle Biotechnology (LSE:CIZ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cizzle Biotechnology (LSE:CIZ)
Historical Stock Chart
From Apr 2023 to Apr 2024